Related Experiment Video
Updated: Jun 28, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Rethinking strategies in SCLC: Lessons learned from tiragolumab in the SKYSCRAPER-02 study
Juan Carlos Laguna1, Laura Mezquita2
1Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Laboratory of Translational Genomics and Targeted therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
Abstract:
The addition of tiragolumab, an anti-TIGIT inhibitor, to chemotherapy plus atezolizumab demonstrated promising early results for lung cancer. Unfortunately, the phase 3 study SKYSCRAPER-02 did not confirm the anticipated benefit of tiragolumab combination in recalcitrant small-cell lung cancer,1 reiterating the need for a more accurate population selection in clinical trials.
Insights
Tiragolumab combined with chemotherapy and atezolizumab showed early promise for lung cancer. However, the SKYSCRAPER-02 trial did not confirm benefits in small-cell lung cancer, highlighting the need for better patient selection.
Area of Science:
- Oncology
- Immunotherapy
- Lung Cancer Research
Background:
- Tiragolumab, an anti-TIGIT antibody, combined with atezolizumab and chemotherapy, showed early promise in lung cancer treatment.
- The TIGIT pathway is a target for cancer immunotherapy, aiming to overcome tumor-induced immune suppression.
Purpose of the Study:
- To evaluate the efficacy and safety of tiragolumab in combination with atezolizumab and chemotherapy in patients with extensive-stage small-cell lung cancer.
- To confirm the promising early findings from previous studies in a larger, phase 3 trial setting.
Main Methods:
- The SKYSCRAPER-02 trial was a randomized, double-blind, placebo-controlled phase 3 study.
- Patients received either tiragolumab plus atezolizumab and chemotherapy or placebo plus atezolizumab and chemotherapy.
Main Results:
- The study did not meet its primary endpoint, failing to demonstrate a significant benefit for the tiragolumab combination over placebo in patients with small-cell lung cancer.
- Early promising results were not replicated in this phase 3 trial, indicating limited efficacy in the studied population.
Conclusions:
- The addition of tiragolumab to chemotherapy plus atezolizumab did not improve outcomes in patients with extensive-stage small-cell lung cancer.
- These findings underscore the critical need for refined patient selection strategies in clinical trials for novel cancer immunotherapies.
